BPC-157 Oral and Nasal: What the Record Shows

Why the route is the question

BPC-157 is sold in three broad forms: injectable vials, capsules or other oral products, and nasal sprays. The injectable is the form the human reports used, and the oral and nasal forms are sold as alternatives to it. Whether they work the same way depends on something that has to be measured rather than assumed: how much of the peptide survives the trip and reaches the blood, which pharmacologists call bioavailability.

Even for injection that figure exists only in animals. In the one formal pharmacokinetic study, in rats and beagle dogs, about 14 to 19 percent of an injection into muscle reached the circulation in rats and 45 to 51 percent in dogs; unchanged BPC-157 had a half-life of under 30 minutes, and it was broken down quickly into small peptide fragments and then single amino acids ^[1]. That study gave the peptide into a vein or a muscle only. It has no oral arm and no nasal arm ^[1].

A 2026 pharmaceutics review of the whole literature put the gap plainly: no pharmaceutical-grade formulation of BPC-157 has been developed or validated, the peptide lacks permeability data, the measurements that show whether a drug can cross the gut wall, and its human pharmacokinetic profile remains critically undercharacterized ^[2].

Does BPC-157 survive the stomach?

The case for oral BPC-157 rests on one repeated claim, that the peptide is stable in human gastric juice. It comes from the Zagreb group that first described the compound and named it after a protein found in gastric juice. A 2020 review by that group calls it "native to and stable in human gastric juice (for more than 24 h)" ^[3], and a 2012 review says it "may be the new drug stable in human gastric juice" ^[4]. Both state stability as a property of the molecule; neither abstract reports the experiment behind it. The 2026 pharmaceutics review repeats the same description ^[2].

Surviving the stomach is also only the first step. A peptide that stays intact in gastric juice still has to cross the lining of the gut and escape the enzymes of the intestine and liver before any of it reaches the blood, and none of those steps has been measured for BPC-157 ^[2]. PubMed indexes 70 records that pair BPC-157 with oral administration, such as the peptide given to rats in drinking water or by stomach tube, and none is indexed as a clinical trial ^[5]. Of the 8 records that pair it with pharmacokinetics, bioavailability or absorption, the only pharmacokinetic study is the injection study above ^{[5, 1]}, and a search for the arginate salt, often described as the stable oral form, returns no record at all ^[5].

Has oral BPC-157 been tested in people?

Once, on paper, and no result has been posted. A phase 1 trial of oral BPC-157 tablets in healthy volunteers, randomized, placebo-controlled and masked, was registered by its sponsor in December 2015 to measure safety and, as secondary outcomes, blood levels over time ^[6]. Its record was last updated the day it was posted, it carries an unknown status, and it has posted no results ^[6]. Of the 4 records PubMed tags as human among the oral studies, none gave BPC-157 to a person by mouth ^[5].

The originating group has also written that a bowel-disease formulation of the peptide, coded PL 14736, was tested in phase II trials ^[4]. PubMed indexes no report of those trials: across every name the peptide goes by, including PL 14736, it holds no record under the clinical-trial publication type ^[7].

The second oral study on the registry is of a different kind. A gummy containing BPC-157 was registered by the company that sells it, with its intervention entered as a dietary supplement; it enrolled 40 people in a single group with no comparison, ran from September to November 2025, was first posted in August 2026 after it had finished, and has posted no results ^[6]. An uncontrolled study of a seller's own product, registered after the fact, cannot show that the peptide was absorbed or that it did anything.

What about BPC-157 nasal spray?

There is no study of it. Across all five names, PubMed holds exactly one record that mentions BPC-157 alongside the nose, and it is not a study of nasal delivery: in a 1997 rat experiment the peptide was injected into the abdomen, and an irritant, capsaicin, was the substance placed in the nose ^{[11, 5]}. ClinicalTrials.gov returns no registered study of nasal BPC-157 ^[6].

FDA has addressed the form directly in enforcement. In a June 2023 warning letter to an online seller, the agency recorded that the firm took orders for "BPC-157" as an injectable and as a nasal spray, and stated that the products it listed were unapproved new drugs ^[12]. The same letter explained the agency's concern with nasal products in general: they "may be rapidly absorbed through the highly vascularized nasal mucosa directly into systemic blood circulation," and if toxic substances are introduced into the nose, harm such as bleeding, ulceration or a hole in the nasal septum may occur ^[12].

Oral versus injection: what can be compared?

Nothing, on the published record. A comparison needs a measurement for each route, and there is an injection figure only in rats and dogs, no oral figure in any species, and no nasal figure at all ^{[1, 2, 5]}. Claims that one form works as well as another, or that a larger oral amount makes up the difference, are not drawn from data, because the data do not exist. The animal numbers themselves cannot be carried over to people ^[2].

The uncertainty about the material is the same in every form. FDA's stated concerns about BPC-157, immune reactions and peptide-related impurities, attach to the substance, and the agency wrote that it lacked sufficient information to know whether the drug would cause harm when given to people ^[13]. The BPC-157 safety record sets out what is and is not known about harm, and the human trial record reads the three injection reports in full.

Is oral or nasal BPC-157 legal?

The route does not change the answer. BPC-157 is not an approved drug in any form, FDA removed it from Category 2 of its compounding list in April 2026 without adding it to Category 1, and the July 2026 advisory committee vote to recommend it for the section 503A list, reported as 8 to 6 with one abstention, is advisory until FDA issues a final rule ^{[14, 15, 16]}. As of September 2026 no licensed pharmacy may lawfully compound it as an injection, a capsule or a spray; the pending status page carries the dated record.

FDA's enforcement record treats BPC-157 as a drug whatever its form. Its 2023 letter called the listed injectable and nasal products new drugs that could not lawfully be sold without approval ^[12], and in October 2020 a Kentucky compounding pharmacy pleaded guilty to distributing unapproved new drugs whose list, in the Justice Department's account of the plea agreement, includes BPC-157 ^[17]. A registry entry that describes a BPC-157 gummy as a dietary supplement is the sponsor's own description, not a finding by FDA ^[6].

For athletes the form is also irrelevant. The World Anti-Doping Agency's 2026 Prohibited List names BPC-157 in section S0, non-approved substances, prohibited at all times, and the list makes no exception for the route ^[18].

Elsewhere in this index